The current uncertainty plaguing US cannabis policy could deter companies across the country from pursuing R&D or teaming up with academia to develop cannabis-based medicines, research industry advocates are warning. Earlier this month, US attorney general Jeff Sessions rescinded guidance ...
read more here
Delivered by @can_nab_is
No comments:
Post a Comment